Stay updated on Biomarker Response to Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the total baseline tumor mutation burden (TMB) evaluation in participants with Stage IV nonsquamous non-small cell lung cancer receiving pembrolizumab combined with chemotherapy in the KEYNOTE-782 clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:28:03.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the required health conditions and prior treatments for inclusion in the study. This change provides more comprehensive information about the criteria researchers use to select participants for the clinical trial.
    Difference
    45%
    Check dated 2024-05-22T21:30:30.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:55:13.000Z thumbnail image

Stay in the know with updates to Biomarker Response to Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page.